US EditionAlvogen unit appeals court loss shielding Bausch Health's IBS drug from generics
Summary by Endpoints News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Bausch Health is successfully battling generics, Raymond James says
Raymond James bullish rating for Bausch Health Companies (Bausch Health Companies NAME Stock Quote, Chart, News, Analysts, Financials NYSE:BHC) remains unchanged after a U.S. District Court ruling on April 17, which granted summary judgment in favour of Bausch Health and Teva, denying Norwich Pharmaceuticals’ attempt to launch a generic version of Xifaxan before January 2028. […] Source
Alvogen unit appeals court loss shielding Bausch Health's IBS drug from generics
Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch Health's Xifaxan to market, the company said. On Friday, its subsidiary Norwich Pharmaceuticals appealed a ...
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
